Suven Pharmaceuticals Limited

SUVENPHAR

INE03QK01018

Pharmaceuticals

End-of-day quote NSE India S.E. Other stock markets 06:00:00 2024-04-28 pm EDT			5-day change	1st Jan Change
650.9 ^INR	-1.33%		+2.11%	-9.95%

Mar. 27	Suven Pharmaceuticals Limited Announces Shifting of Registered Office	CI
Mar. 05	Transcript : Cohance Lifesciences Limited, Suven Pharmaceuticals Limited - M&A Call

Suven Pharmaceuticals Limited Approves Interim Dividend for the Financial Year 2023-24

December 15, 2023 at 08:08 am EST

Suven Pharmaceuticals Limited announced that at its annual general meeting of the company held on December 15, 2023, approved and ratified the Interim Dividend on Equity Shares INR 6.00 per equity share for the financial year 2023-24.

Latest news about Suven Pharmaceuticals Limited

Suven Pharmaceuticals Limited Announces Shifting of Registered Office	Mar. 27	CI
Transcript : Cohance Lifesciences Limited, Suven Pharmaceuticals Limited - M&A Call	Mar. 05
Indian shares set to rise on strong domestic growth, in-line US inflation data	Feb. 29	RE
Suven Pharmaceuticals Limited agreed to acquire Cohance Lifesciences Limited.	Feb. 28	CI
US FDA Clears Suven Pharmaceuticals' API and Formulations Plants in Hyderabad, India	Feb. 23	MT
Suven Pharmaceuticals' Consolidated Net Profit Declines in Fiscal Q3	Feb. 06	MT
Transcript : Suven Pharmaceuticals Limited, Q3 2024 Earnings Call, Feb 05, 2024	Feb. 05
Suven Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 05	CI
Suven Pharmaceuticals CFO Steps Down	Dec. 25	MT
Suven Pharmaceuticals Limited Announces CFO Changes, Effective January 2, 2024	Dec. 22	CI
Suven Pharmaceuticals Names CFO	Dec. 21	MT
Suven Pharmaceuticals Limited Appoints Dr. Vetukuri Venkata Naga Kali Vara Prasada Raju as Managing Director	Dec. 15	CI
Suven Pharmaceuticals Limited Announces Board Appointments	Dec. 15	CI
Suven Pharmaceuticals Limited Approves Interim Dividend for the Financial Year 2023-24	Dec. 15	CI
Suven Pharmaceuticals Limited Proposes Interim Dividend for the Financial Year 2022-23	Nov. 22	CI
Suven Pharmaceuticals Posts Gains in Fiscal Q2 Consolidated Profit	Nov. 14	MT
Suven Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 09	CI
Transcript : Suven Pharmaceuticals Limited, Q2 2024 Earnings Call, Nov 09, 2023	Nov. 09
Berhyanda Limited completed the acquisition of 0.001% stake in Suven Pharmaceuticals Limited for INR 1.3 million.	Nov. 02	CI
Suven Pharmaceuticals Limited Announces Board Changes	23-09-29	CI
Advent International Corporation completed the acquisition of 50.1% stake in Suven Pharmaceuticals Limited from Jasti Family.	23-09-28	CI
INDIA STOCKS-India's Nifty 50, Sensex scale new peaks on hopes of Fed rate pause	23-09-14	RE
Indian shares set to open higher on rising hopes of a Fed rate pause	23-09-13	RE
Transcript : Suven Pharmaceuticals Limited, Q1 2024 Earnings Call, Aug 10, 2023	23-08-10
Suven Pharmaceuticals Clocks Gains in Fiscal Q1 Consolidated Net Profit	23-08-09	MT

Chart Suven Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Suven Pharmaceuticals Limited is an India-based company. The Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Specialty Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology, and chemical companies. The Company operates through Pharmaceuticals Manufacturing and Services segment. Its geographical segments include India, the United States, Europe, and others. In India, the Company sells bulk drugs and intermediates, chemicals, and services. In the United States, the Company sells intermediates and services. In Europe, the Company sells bulk drugs and intermediates. In other countries, the Company sells bulk drugs, intermediates, and services. The Companyâs wholly owned subsidiary is Suven Pharma Inc.

Sector

Pharmaceuticals

Calendar

2024-06-19 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Suven Pharmaceuticals Limited

Trading Rating

Investor Rating

ESG Refinitiv

D-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

650.9 INR

Average target price

685.5 INR

Spread / Average Target

+5.32%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SUVEN PHARMACEUTICALS LIMITED	-9.95%	1.99B
ELI LILLY AND COMPANY	+26.47%	664B
NOVO NORDISK A/S	+26.74%	567B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+19.35%	330B
ABBVIE INC.	+4.23%	286B
ASTRAZENECA PLC	+13.43%	234B
NOVARTIS AG	+4.71%	199B
ROCHE HOLDING AG	-9.53%	196B
AMGEN INC.	-4.04%	148B

Other Pharmaceuticals